Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jan J. van Lier"'
Autor:
Eleanor Harrison-Moench, Jan J. van Lier, Jennifer Dong, Angelika Bachmann, David Mitchell, Andreas Port, Nadra Mammasse, Annick Seithel-Keuth, Martin Dyroff, William Tracewell, Holger Scheible
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2420-2430 (2021)
Clinical and Translational Science
Clinical and Translational Science
The highly selective, covalent Bruton’s tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indicated tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::918d725112442079a32e919b8e766712
https://doi.org/10.1111/cts.13108
https://doi.org/10.1111/cts.13108
Autor:
Andreas Johne, Andreas Becker, Holger Scheible, Jan J. van Lier, Andreas Kovar, Oliver von Richter
Publikováno v:
The Journal of Clinical Pharmacology. 55:815-824
Cilengitide (EMD 121974, manufactured by Merck KGaA, Darmstadt, Germany) is an αv-integrin receptor antagonist showing high affinity for αvβ3 and αvβ5.This study determined the mass balance of cilengitide in healthy volunteers receiving a single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b9b895fe0c66d19c914eb456439b19a
https://doi.org/10.1002/jcph.482
https://doi.org/10.1002/jcph.482
Autor:
André A. vanVliet, Younggil Kwon, Tanya Watanabe, Richard S. Geary, Jan J van Lier, JoAnn D Bradley, Mark K. Wedel
Publikováno v:
Clinical Pharmacokinetics. 45:789-801
ISIS 113715 is a 20-mer phosphorothioate antisense oligonucleotide (ASO) that is complementary to the protein tyrosine phosphatase 1B (PTP-1B) messenger RNA and subsequently reduces translation of the PTP-1B protein, a negative regulator of insulin r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a8e9efc7cfa73d32f0c0b6651f4df1a
https://doi.org/10.2165/00003088-200645080-00003
https://doi.org/10.2165/00003088-200645080-00003
Autor:
Thomas Meinicke, Henrieke de Bruin, Jan J. van Lier, Joachim Stangier, Pauline N. M. Van Heiningen, W.J Tamminga, Chung‐An P. F. Su, Jan H. G. Jonkman
Publikováno v:
Journal of Cardiovascular Pharmacology. 38:672-685
Telmisartan is a new angiotensin receptor antagonist possessing potent, selective, and insurmountable inhibitory activity specific to the angiotensin II type 1 (AT 1 ) receptor. The current study was performed to determine the inhibition of the angio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec233a175038d61c66576130a0d3ac60
https://doi.org/10.1097/00005344-200111000-00004
https://doi.org/10.1097/00005344-200111000-00004
Autor:
Frans A. E. Sollie, B. Oosterhuis, Chung‐An P. F. Su, Jan H. G. Jonkman, Jan J. van Lier, Maarten G. C. Hendriks, Joachim Stangier
Publikováno v:
The Journal of Clinical Pharmacology. 40:1331-1337
The effects of multiple-dose telmisartan on the steady-state pharmacodynamics and pharmacokinetics of warfarin were assessed in 12 healthy young males in an open-label, single-period study conducted over 30 days. Subjects received loading doses of or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a82d46e0c009d5ad7e13a671ced964a5
https://doi.org/10.1177/009127000004001204
https://doi.org/10.1177/009127000004001204
The Effect of Telmisartan on the Steady‐State Pharmacokinetics of Digoxin in Healthy Male Volunteers
Autor:
Jan J. van Lier, B. Oosterhuis, Joachim Stangier, Frans A. E. Sollie, Chung‐An P. F. Su, Jan H. G. Jonkman, Maarten G. C. Hendriks
Publikováno v:
The Journal of Clinical Pharmacology. 40:1373-1379
A multiple-dose, open-label, two-period, crossover randomized study was conducted in 12 healthy male volunteers to investigate the effect of multiple-dose telmisartan on the steady-state pharmacokinetics of digoxin. On day 1 of a 7-day medication per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f4d6f7b4d2c85efb9c0bcbcb286890b
https://doi.org/10.1177/009127000004001209
https://doi.org/10.1177/009127000004001209
Autor:
John Allanson, Deborah A. Smith, Richard Peck, Nanco R. Hefting, Jan J. van Lier, Emma J. Seaber, Frans A. E. Sollie, Johan Wemer, Jan H. G. Jonkman
Publikováno v:
British Journal of Clinical Pharmacology. 46:433-439
Aims Zolmitriptan (Zomig (formerly 311C90)) is a novel 5-HT1B/1D receptor agonist developed for the acute oral treatment of migraine. A highly sensitive LCMS-MS assay has been developed which allows quantification of plasma concentrations of zolmitri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20e6deefe44da66cfe877a91e5a5f66b
https://doi.org/10.1046/j.1365-2125.1998.00809.x
https://doi.org/10.1046/j.1365-2125.1998.00809.x
Publikováno v:
Acta Obstetricia et Gynecologica Scandinavica. 69:505-509
In a group of 20 asymptomatic women at increased risk for ectopic pregnancy, serum analyses were conducted prospectively early in pregnancy (amenorrhea less than or equal to 45 days) at 2-4-day intervals, to examine the rate of increase in hCG values
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14e9d3d08bda38f050a2f8645e0217c0
https://doi.org/10.3109/00016349009013327
https://doi.org/10.3109/00016349009013327
Autor:
Becker, Andreas, von Richter, Oliver, Kovar, Andreas, Scheible, Holger, van Lier, Jan J., Johne, Andreas
Publikováno v:
Journal of Clinical Pharmacology; Jul2015, Vol. 55 Issue 7, p815-824, 10p
Autor:
Stangier, Joachim, Su, Chung-An P. F., van Heiningen, Pauline N. M., Meinicke, Thomas, van Lier, Jan J., de Bruin, Henrieke, Tamminga, Wim J., Jonkman, Jan H. G.
Publikováno v:
Journal of Cardiovascular Pharmacology; Nov2001, Vol. 38 Issue 5, p672-685, 14p